Mechanisms and Research Advances of SGLT2i in Heart Failure and Arrhythmia
Abstract：Heart failure is the final stage of various cardiovascular diseases. Although there have been significant advances in prevention and drug treatment, heart failure (HF) still has a high incidence and mortality rate. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a new type of oral antidiabetic drug with good cardiovascular protective effects. In recent years, there is clear evidence that SGLT2i can significantly reduce the hospitalization rate and mortality of heart failure, as well as the risk of cardiovascular death, regardless of whether diabetes is present.
Machine-generated Keywords：
Publication Date：2025-05-20
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 636-640 )